Brief: Spyre Announces Acceleration Of Expected Topline Readout Of Skyway Rheumatoid Arthritis Sub-Study To Q3 2026
16/03/2026 12:13
March 16 (Reuters) - Spyre Therapeutics Inc SYRE.O: SPYRE ANNOUNCES ACCELERATION OF EXPECTED TOPLINE READOUT OF SKYWAY RHEUMATOID ARTHRITIS SUB-STUDY TO Q3 2026 SPYRE THERAPEUTICS INC - PSA AND AXSPA SUB-STUDY RECRUITMENT ON TRACK; TOPLINE DATA EXPECTED Q4 2026 SPYRE THERAPEUTICS INC - SKYLINE UC TRIAL ENROLLING AHEAD OF SCHEDULE; PART A READOUTS BEGIN Q2 2026 Source text: ID:nGNX6VZDJK Further company coverage: SYRE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spyre Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
U.S. STOCKS ON THE MOVE-MYR Group, Spyre Therapeutics, AMD
Spyre Therapeutics slips on $350 mln share sale
Brief: Spyre Therapeutics Announces Pricing Of $350.0 Million Public Offering Of Common Stock